Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.

Cell Death Dis · 2018 · PMC5833482 · PMID 29348495

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Furthermore, MTS assays showed that Mcl-1 knockdown (KD) significantly sensitized Hep3B and SNU475 cells to MLN2238 treatment compared with cells transfected with control siRNA (siNC), whereas although a reduction of cell viability was observed in HepG2 cells after Mcl-1 KD, differences did not reach statistical significance (Fig. 5c , right side).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.